Evidence map›Paper›PMID 39857949›Full record

ReviewCancers2025

A Scoping Review of Primary Breast Cancer Risk Reduction Strategies in East and Southeast Asia.

Filipa Alpeza, Christine Kim Yan Loo, Qingyuan Zhuang, Mikael Hartman, Serene Si Ning Goh, Jingmei Li

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Filipa AlpezaGenome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore 138672, Singapore.
Christine Kim Yan LooGenome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore 138672, Singapore.ORCID 0009-0007-3689-3970
Qingyuan ZhuangDivision of Supportive and Palliative Care, National Cancer Centre Singapore, Singapore 168583, Singapore.ORCID 0000-0001-8770-9968
Mikael HartmanSaw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore 117549, Singapore.
Serene Si Ning GohSaw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore 117549, Singapore.ORCID 0000-0003-4916-2142
Jingmei LiGenome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore 138672, Singapore.ORCID 0000-0001-8587-7511

Funding

Agency of Science, Technology and Research (A*STAR)
6 · The paper itself

Abstract

Breast cancer (BC) screening enables early detection and timely treatment of cancer. Improving the effectiveness of BC screening can be accomplished by personalizing screening schedules according to each woman's specific risk level. However, when informing women about their risk classification, especially those at high risk, it is important to give clear recommendations on how to lower their risk. BC risk reduction comprises lifestyle modifications, preventive surgery, and chemoprevention, with the latter two being particularly applicable to high-risk individuals. Public health guidance on risk-reducing interventions is heterogeneous and context-dependent. We conducted a scoping review on BC surgical interventions and chemoprevention in East and Southeast Asia in publications between 2010 and 2024. We searched two databases and identified 23 publications relevant for inclusion. The highest number of publications came from South Korea (

Indexed as

Asiabreast cancercancer preventionchemopreventioninterventionlose-dose tamoxifenprophylacticrisk-based screeningrisk predictionrisk reductionscoping reviewsurgerytamoxifen

Identifiers

PMID39857949
PMCPMC11763974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.